Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial

BACKGROUND: The DAPA‐CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin reduced the risk of kidney and cardiovascular events in patients with chronic kidney disease and albuminuria with and without type 2 diabetes. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Chertow, Glenn M., Correa‐Rotter, Ricardo, Vart, Priya, Jongs, Niels, McMurray, John J. V., Rossing, Peter, Langkilde, Anna Maria, Sjöström, C. David, Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227210/
https://www.ncbi.nlm.nih.gov/pubmed/37119064
http://dx.doi.org/10.1161/JAHA.122.028739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227210/
https://www.ncbi.nlm.nih.gov/pubmed/37119064
http://dx.doi.org/10.1161/JAHA.122.028739

Ejemplares similares